Healthcare & Biotech

San Francisco – – September 11, 2026 -- Trust AI has wired VELMENI's FDA-cleared dental imaging AI directly into its Isaac PracticeOS platform, connecting radiographic diagnosis to a $299-per-month automated claims pipeline that has already recovered months of unbilled revenue at a California practice.

Isaac's agent swarm assembles claims the moment a dentist confirms a VELMENI finding

The integration places VELMENI for DENTISTS (V4D) 2D/3D radiographic analysis inside Isaac's RCM Hub, where automated agents identify payer-specific documentation requirements, select matching billing codes, and attach supporting radiographs before a claim is submitted. Every claim is reviewed by a licensed dentist and a billing specialist before it leaves the system. Trust AI CEO Bernard Casse said the company "wired it into the bloodstream" rather than treating the AI read as a standalone sidebar feature.

Danbury, Conn. – September 11, 2026 -- Perosphere Technologies Inc. announced that a clinical study evaluating its ClotChek point-of-care coagulometer has been published in the peer-reviewed journal Thrombosis and Haemostasis, confirming the device's ability to detect anticoagulation levels in patients on Factor Xa inhibitors apixaban and rivaroxaban.

Study confirms ClotChek detects DOAC anticoagulation at two clinical thresholds

The research measured ClotChek Clotting Time (CKCT) against anti-FXa drug levels in patients on direct oral anticoagulants, finding strong correlations when categorized by Medical Decision Limits. The device demonstrated the ability to identify clinically meaningful anticoagulation at both the >75 ng/mL and >30 ng/mL thresholds, including sensitivity at lower drug concentrations.

New York – September 11, 2026 -- Eligible, Inc. has completed its SOC 2 Type II examination for its Platform Services System with zero exceptions across all four Trust Services Categories evaluated: Security, Availability, Processing Integrity, and Confidentiality.

Independent assessor A-LIGN confirms full compliance across audit period

The examination, conducted by third-party assessor A-LIGN, evaluated the design and operating effectiveness of Eligible's controls over a defined audit period, covering the REST APIs, application infrastructure, and supporting services that process HIPAA-mandated healthcare financial transactions. These include eligibility verification (270/271), claims (837/276/277), remittance (835), and acknowledgements (TA1, 997, 999).

Delray Beach, Fla. – September 11, 2026 -- The global medical supplies market is projected to grow from $194.76 billion in 2026 to $248.03 billion by 2031, a compound annual growth rate of 7.39%, according to new research from MarketsandMarkets.

Asia Pacific outpaces global growth rate as diagnostic demand accelerates

Asia Pacific is set to register the fastest regional CAGR at 10.2% through 2031, outstripping the global average as healthcare infrastructure expands across the region. By product type, infusion and injectable supplies will grow fastest at a 9.0% CAGR, while diagnostic supplies held the largest share in 2025 and are expected to post the quickest growth of any category over the forecast period, driven by rising chronic and infectious disease burdens and expanding preventive screening programs.

Stamford, Conn. – – September 11, 2026 -- Curaleaf Holdings, Inc. released a fact sheet countering what it called inaccurate statements by Aurora Cannabis Inc. regarding Curaleaf's proposal to acquire the company, arguing its offer represents one of the highest premiums in a decade of Canadian M&A.

Curaleaf says its bid carries a 110% premium once Aurora's cash is excluded

Curaleaf's headline offer reflects a 45% premium, which the company says ranks among the higher Canadian M&A premiums of the past ten years. Stripping out cash on Aurora's balance sheet, Curaleaf calculates the effective premium at 110%. Curaleaf noted Aurora has continued issuing shares through an At-the-Market program at prices below the value implied by the offer, even after the bid was made public.

Stockholm – September 11, 2026 -- SciBase Holding AB (STO: SCIB) has received an additional order worth roughly $0.6 million, or approximately SEK 5 million, from Castle Biosciences (NASDAQ: CSTL) to accelerate an ongoing clinical study and prepare a second trial under their dermatology collaboration.

Order covers Nevisense Go devices and electrodes for atopic dermatitis research

The order includes both SciBase's portable Nevisense Go pen device and associated electrodes. Deliveries are scheduled to begin in the fourth quarter of 2026.

Collaboration targets relapse prediction in atopic dermatitis patients

SciBase and Castle Biosciences entered a collaboration and license agreement in 2025. The first joint study under that agreement aims to predict relapses in atopic dermatitis and is currently underway, with the new order funding both faster progression of that trial and groundwork for a follow-up study.

Berlin – September 11, 2026 -- Germany's Federal Medical Association (Bundesärztekammer) has confirmed support for a cross-sector reform of acute and emergency care, while pushing for amendments before the bill clears parliament.

Reinhardt calls for unified triage system across Germany

Association president Dr. Klaus Reinhardt told the Bundestag Health Committee ahead of a hearing on the draft law that the reform must introduce "genuine care management" needed across other healthcare sectors too. He said a nationwide, standardized initial assessment system is required to ensure patients are directed reliably through the system, with responsibility resting with physician self-governance bodies.

Dallas – September 11, 2026 -- NFL All-Pro Micah Parsons has taken an equity stake and board seat at RejuvStem, a Cancún, Mexico-based regenerative wellness company, as the firm looks to widen its footprint beyond athletic recovery into the broader preventive health market.

Parsons moves from endorsement to equity investor and board member

The deal, negotiated by Athletes First, the sports representation and marketing agency that handles Parsons' on- and off-field business, gives him formal roles as investor, board member and brand ambassador rather than a standard sponsorship arrangement. He will advise RejuvStem on brand growth and strategic initiatives, working to position the company's regenerative therapies and personalized wellness programs to a wider consumer base that includes non-athletes seeking preventive care.

Hartford, Conn. – September 11, 2026 -- IVI RMA North America has partnered with Illume Fertility, adding the Connecticut-based provider's five clinics across Connecticut and New York to its regional network. The deal extends IVI RMA's existing Northeast footprint, which includes operations in Boston and New Jersey, into a more integrated multi-state fertility care corridor.

Illume brings nine board-certified specialists into the IVI RMA fold

Illume Fertility's clinical team consists of nine fertility specialists, each board-certified in reproductive endocrinology and infertility as well as obstetrics and gynecology. The physicians hold fellowship training in fertility treatment, hormone regulation, and assisted conception.

New York – September 11, 2026 -- PulsePoint has expanded its Audience Manager platform to YouTube, enabling pharma and healthcare marketers to activate and measure verified, NPI-level physician audiences on the video platform for the first time.

Early campaigns show 1.9x higher click-through rates using verified targeting

In early activations, campaigns using Audience Manager target lists on YouTube generated a 1.9x higher click-through rate compared to broad demographic targeting, according to PulsePoint. The company's DirectMatch technology deterministically matches verified NPI audiences directly onto YouTube campaigns, addressing a gap where video platforms previously lacked prescriber-level precision for media buyers.